POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid volume, acid-base balance, nerve impulse transmission, and muscle contraction. Dextrose provides calories and can promote protein-sparing and hepatic glycogen deposition. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid volume and osmolality.
| Metabolism | Potassium: primarily excreted unchanged by kidneys (90%), with minor fecal loss; dextrose: metabolized via glycolysis and oxidative pathways; sodium and chloride: predominantly excreted by kidneys with regulation via aldosterone and other hormones. |
| Excretion | Potassium is primarily excreted renally (90%), with approximately 10% eliminated via the gastrointestinal tract. Excretion is influenced by aldosterone, acid-base balance, and renal function. |
| Half-life | The terminal half-life of potassium is not typically defined, but distribution half-life is approximately 1-1.5 hours. Whole-body turnover is 2-4 hours, but renal impairment prolongs elimination. |
| Protein binding | Potassium is not significantly protein-bound (<2%). Free ionized form is pharmacologically active. |
| Volume of Distribution | Apparent Vd is approximately 4-5 L/kg (total body water). Potassium distributes primarily intracellularly (98% of body potassium is in cells). |
| Bioavailability | Oral: approximately 90% absorbed; IV: 100% bioavailable. Intestinal absorption is passive and nearly complete. |
| Onset of Action | Intravenous infusion: minutes (immediate effect on serum potassium). Oral: 1-2 hours for peak serum levels. |
| Duration of Action | Intravenous: effects persist for 2-4 hours post-infusion. Oral: up to 6 hours. Duration depends on ongoing losses and redistribution. |
Intravenous infusion: Administer at a rate of 10-20 mEq/hour, not to exceed 200 mEq in 24 hours. The specific dose depends on the patient's electrolyte needs and fluid status. Typical maintenance: 20-40 mEq of potassium per day.
| Dosage form | INJECTABLE |
| Renal impairment | GFR < 30 mL/min: Reduce potassium dose by 50% or avoid use. GFR 30-50 mL/min: Reduce dose by 25%. Monitor serum potassium frequently. GFR > 50 mL/min: No adjustment. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce potassium dose by 25%. Child-Pugh Class C: Reduce potassium dose by 50% and monitor serum potassium closely. |
| Pediatric use | Neonates and infants: 1-2 mEq/kg/day intravenously, not to exceed 0.5-1 mEq/kg/hour. Children: 2-3 mEq/kg/day, with a maximum rate of 0.5 mEq/kg/hour. Adjust based on serum potassium levels. |
| Geriatric use | Start at lower end of adult dosing (e.g., 10 mEq/day) and titrate based on renal function, as elderly patients often have reduced GFR. Monitor serum potassium and renal function frequently. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium chloride, dextrose, and sodium chloride are normal constituents of human milk. Administration of this solution is unlikely to significantly alter milk composition or affect the nursing infant. The M/P ratio is not applicable as these are endogenous substances. Use during breastfeeding is considered compatible; however, monitor maternal fluid and electrolyte status to avoid imbalances that could indirectly affect milk production. |
| Teratogenic Risk |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia (serum potassium >5.0 mEq/L)","Severe renal impairment with oliguria or anuria","Untreated Addison's disease","Acute dehydration","Concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride)","Crush syndrome or severe hemolytic reactions","Known hypersensitivity to any component"]
| Precautions | ["Risk of hyperkalemia, especially in patients with renal impairment, adrenal insufficiency, or those receiving potassium-sparing diuretics or ACE inhibitors","Monitor serum potassium levels and ECG during administration","Avoid rapid infusion to prevent hyperkalemia and cardiac arrhythmias","Use with caution in patients with cardiac disease, metabolic acidosis, or conditions predisposing to hyperkalemia","Do not administer if solution is discolored or contains particulate matter"] |
Loading safety data…
| Potassium chloride is a normal constituent of body fluids and, at therapeutic doses, does not pose a teratogenic risk. In dextrose 5% and sodium chloride 0.45%, no increased risk of fetal malformations has been associated with use during pregnancy. However, administration of large volumes of intravenous fluids may cause fluid and electrolyte imbalances that could affect the fetus. There is no evidence of teratogenicity from dextrose or sodium chloride at standard concentrations. |
| Fetal Monitoring | Monitor maternal serum electrolytes (potassium, sodium), glucose, fluid balance, and renal function. Assess for signs of hyperkalemia (e.g., cardiac arrhythmias, muscle weakness) or fluid overload. Fetal monitoring (e.g., heart rate) may be warranted if maternal electrolyte disturbances occur. In pregnancy, consider non-stress test or biophysical profile if maternal condition warrants. |
| Fertility Effects | No adverse effects on fertility are anticipated at therapeutic doses. Potassium chloride, dextrose, and sodium chloride are essential nutrients and do not impair reproductive function. No studies have shown negative impacts on fertility from use of this solution. |